Profil Pengobatan Berbasis Platinum pada Pasien KPKBSK Stadium III di RS X
DOI:
https://doi.org/10.29313/bcsp.v6i2.24914Keywords:
KPKBSK, Stadium III, PlatinumAbstract
Abstract. Non-Small Cell Lung Cancer (NSCLC) is the most common type of lung cancer, with the majority of patients newly diagnosed at stage III. Platinum-based combination chemotherapy (platinum doublet) is the primary systemic treatment option for controlling disease progression. This study aims to determine the profile of platinum-based treatment and the characteristics of stage III NSCLC patients at Hospital X. This study employed a retrospective observational design using a cohort approach. The sample was selected using total sampling from secondary medical record data of stage III NSCLC patients who met the inclusion criteria and received their fourth cycle of platinum-based chemotherapy. The results showed that of the 90 patients, the majority were male (76.7%) and aged 60 years or older (63.3%). The majority of patients are employed (90.0%), had a history of smoking (51.1%), had adenocarcinoma as the histopathological type (58.8%), were in stage III C (52.2%), and had comorbidities such as COPD or other lung diseases (48.7%). The most commonly used platinum-based chemotherapy regimens were carboplatin + paclitaxel (53.3%), followed by cisplatin + pemetrexed (20.0%), and cisplatin + paclitaxel (16.7%). These findings provide an overview of patient characteristics and platinum-based treatment profiles to inform improved treatment strategies for patients with stage III NSCLC.
Abstrak. Kanker paru jenis karsinoma bukan sel kecil (KPKBSK) merupakan jenis kanker paru terbanyak, di mana sebagian besar pasien baru terdiagnosis pada stadium III. Kemoterapi kombinasi berbasis platinum (platinum-doublet) menjadi pilihan utama terapi sistemik untuk mengontrol progresivitas penyakit. Penelitian ini bertujuan untuk mengetahui profil pengobatan berbasis platinum dan karakteristik pasien KPKBSK stadium III di Rumah Sakit X. Penelitian ini menggunakan desain observasional retrospektif dengan pendekatan kohort. Sampel diambil dengan teknik total sampling dari data sekunder rekam medis pada pasien KPKBSK stadium III yang memenuhi kriteria inklusi dan menerima kemoterapi berbasis platinum siklus ke-4. Hasil penelitian menunjukkan bahwa dari 90 pasien, didominasi oleh laki-laki (76,7%) dengan kelompok usia ≥ 60 tahun (63,3%). Mayoritas pasien bekerja (90,0%), memiliki riwayat merokok (51,1%), dengan jenis histopatologi adenokarsinoma (58,8%), stadium III C (52,2%), dan memiliki komorbiditas PPOK atau penyakit paru lainnya (48,7%). Kelompok kemoterapi berbasis platinum yang banyak digunakan adalah kelompok carboplatin + paclitaxel (53,3%), diikuti cisplatin + pemetrexed (20,0%), dan cisplatin + paclitaxel (16,7%). Temuan ini memberikan gambaran umum terkait karakteristik pasien dan profil pengobatan berbasis platinum untuk meningkatkan strategi pengobatan pada pasien KPKBSK stadium III.
References
Alexander, M., Kim, S. Y., & Cheng, H. (2020). Update 2020: Management of Non-Small Cell Lung Cancer. In Lung (Vol. 198, Number 6, pp. 897–907). Springer. https://doi.org/10.1007/s00408-020-00407-5
Amin, M. B., Greene, F. L., Edge, S. B., Compton, C. C., Gershenwald, J. E., Brookland, R. K., Meyer, L., Gress, D. M., Byrd, D. R., & Winchester, D. P. (2017). The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging . CA: A Cancer Journal for Clinicians, 67(2), 93–99. https://doi.org/10.3322/caac.21388
Antonelli, G., Libra, M., Panebianco, V., Russo, A. E., Vitale, F. V., Colina, P., D’angelo, A., Rossello, R., & Ferraù, F. (2016). Molecular-targeted therapy for elderly patients with advanced non-small cell lung cancer (Review). In Oncology Letters (Vol. 11, Number 1, pp. 3–8). Spandidos Publications. https://doi.org/10.3892/ol.2015.3901
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., Cho, B. C., Bourhaba, M., Quantin, X., Tokito, T., Mekhail, T., Planchard, D., Kim, Y.-C., Karapetis, C. S., Hiret, S., … Özgüroğlu, M. (2017). Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer. New England Journal of Medicine, 377(20), 1919–1929. https://doi.org/10.1056/nejmoa1709937
Bade, B. C., & Dela Cruz, C. S. (2020). Lung Cancer 2020: Epidemiology, Etiology, and Prevention. In Clinics in Chest Medicine (Vol. 41, Number 1, pp. 1–24). W.B. Saunders. https://doi.org/10.1016/j.ccm.2019.10.001
Czira A, & Pacheco L. (2016). Cancer Drugs in The EU5 and USA: Cross-Country Pricing Comparison and Correlation Analysis Between Overall Survival (OS) and Progression-Free Survival (PFS). Value in Health, 19(7), A717. https://doi.org/10.1016/j.jval.2016.09.2123
Detterbeck, F. C. (2018). The eighth edition TNM stage classification for lung cancer: What does it mean on main street? In Journal of Thoracic and Cardiovascular Surgery (Vol. 155, Number 1, pp. 356–359). Mosby Inc. https://doi.org/10.1016/j.jtcvs.2017.08.138
DiPiro, J. T., Ellingrod, V. L., Posey, L. M., Nolin, T. D., Haines, S. T., & Yee, G. C. (2023). DiPiro’s Pharmacotherapy: A Pathophysiologic Approach 12 Th Edition.
Durham, A. L., & Adcock, I. M. (2015). The relationship between COPD and lung cancer. In Lung Cancer (Vol. 90, Number 2, pp. 121–127). Elsevier Ireland Ltd. https://doi.org/10.1016/j.lungcan.2015.08.017
Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., D’Amico, T. A., DeCamp, M., Dilling, T. J., Dowell, J., Gettinger, S., Grotz, T. E., Gubens, M. A., Hegde, A., Lackner, R. P., Lanuti, M., … Hughes, M. (2022). Non-Small Cell Lung Cancer, Version 3.2022. JNCCN Journal of the National Comprehensive Cancer Network, 20(5), 497–530. https://doi.org/10.6004/jnccn.2022.0025
Haupt, S., Caramia, F., Klein, S. L., Rubin, J. B., & Haupt, Y. (2021). Sex disparities matter in cancer development and therapy. In Nature Reviews Cancer (Vol. 21, Number 6, pp. 393–407). Nature Research. https://doi.org/10.1038/s41568-021-00348-y
Herbst, R. S., Morgensztern, D., & Boshoff, C. (2018). The biology and management of non-small cell lung cancer. In Nature (Vol. 553, Number 7689, pp. 446–454). Nature Publishing Group. https://doi.org/10.1038/nature25183
kim, J., Hobart and Huang, & Brian W. (2022). Lung cancer: diagnosis, treatment principles, and screening. American Family Physician, 105.
Komite Penanggulangan Kanker Nasional. (2022). Panduan Penatalaksanaan Kanker Paru.
Menteri Kesehatan Republik Indonesia. (2023). Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/1438/2023 tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana Kanker Paru.
Nirmalasari. (2022). PASIEN KANKER PARU KARSINOMA BUKAN SEL KECIL (KPKBSK) STADIUM LANJUT EFFICACY AND SAFETY OF FIRST LINE CHEMOTERAPY FOR ADVANCED STAGE NON-SMALL CELL LUNG CARCINOMA (NSCLC).
Rianyta, Louisa Melva, Syahruddin Elisna, & Soetikno, V. (2021). Observational Study of Paclitaxel-Carboplatin versus Pemetrexed-Carboplatin for Advanced Pulmonary Adenocarcinoma at Referral Hospital in Jakarta Studi Observasi Paclitaxel-Carboplatin versus Pemetrexed-Carboplatin untuk Terapi Adenokarsinoma Paru Lanjut di Rumah Sakit Rujukan di Jakarta. 9(3), 2021. https://doi.org/10.23886/ejki.9.16.178
Ricciuti, B., Alessi, J. V., Elkrief, A., Wang, X., Cortellini, A., Li, Y. Y., Vaz, V. R., Gupta, H., Pecci, F., Barrichello, A., Lamberti, G., Nguyen, T., Lindsay, J., Sharma, B., Felt, K., Rodig, S. J., Nishino, M., Sholl, L. M., Barbie, D. A., … Luo, J. (2022). Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer. Annals of Oncology, 33(10), 1029–1040. https://doi.org/10.1016/j.annonc.2022.07.005
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249. https://doi.org/10.3322/caac.21660
Swanton, C., Hill, W., Lim, E., Lee, C., Weeden, C. E., Augustine, M., Chen, K., Kuan, F.-C., Marongiu, F., Rodrigues, F., Cha, H., Jacks, T., Luchtenborg, M., Malanchi, I., Downward, J., Carlsten, C., Hackshaw, A., Litchfield, K. R., DeGregori, J., & Jamal-Hanjani, M. (2022). LBA1 Mechanism of action and an actionable inflammatory axis for air pollution induced non-small cell lung cancer: Towards molecular cancer prevention. Annals of Oncology, 33, S1413. https://doi.org/10.1016/j.annonc.2022.08.046
Travis, W. D., Brambilla, E., Nicholson, A. G., Yatabe, Y., Austin, J. H. M., Beasley, M. B., Chirieac, L. R., Dacic, S., Duhig, E., Flieder, D. B., Geisinger, K., Hirsch, F. R., Ishikawa, Y., Kerr, K. M., Noguchi, M., Pelosi, G., Powell, C. A., Tsao, M. S., & Wistuba, I. (2015). The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances since the 2004 Classification. In Journal of Thoracic Oncology (Vol. 10, Number 9, pp. 1243–1260). Elsevier Inc. https://doi.org/10.1097/JTO.0000000000000630
WHO. (2022). Global Cancer Observatory. Https://Gco.Iarc.Who.Int/Today/En/Dataviz/Pie?Mode=population&group_populations=0.
Zeng, X., Zhu, S., Xu, C., Wang, Z., Su, X., Zeng, D., Long, H., & Zhu, B. (2020). Effect of comorbidity on outcomes of patients with advanced non-small cell lung cancer undergoing anti-PD1 immunotherapy. Medical Science Monitor, 26. https://doi.org/10.12659/MSM.922576
Zhang, C., Xu, C., Gao, X., & Yao, Q. (2022). Platinum-based drugs for cancer therapy and anti-tumor strategies. In Theranostics (Vol. 12, Number 5, pp. 2115–2132). Ivyspring International Publisher. https://doi.org/10.7150/thno.69424
